Evidence map›Paper›PMID 32156255›Full record

ArticleBMC medical research methodology2020

Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder.

Hoda Shirafkan, Javad Mahmoudi-Gharaei, Akbar Fotouhi, Seyyed Ali Mozaffarpur, Mehdi Yaseri, Mostafa Hoseini

Open access · goldAbstract read
In one paragraph

Article in BMC medical research methodology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hoda ShirafkanSocial Determinants of Health (SDH) Research Centre, Research Institute for Health, Babol University of Medical Sciences, Babol, Iran.
Javad Mahmoudi-GharaeiPsychiatry and Psychology Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Akbar FotouhiDepartment of Epidemiology and Biostatistics, School of public health, Tehran University of Medical Sciences, Tehran, Iran.
Seyyed Ali MozaffarpurTraditional Medicine and History of Medical Sciences Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
Mehdi YaseriDepartment of Epidemiology and Biostatistics, School of public health, Tehran University of Medical Sciences, Tehran, Iran. m.yaseri@gmail.com.
Mostafa HoseiniDepartment of Epidemiology and Biostatistics, School of public health, Tehran University of Medical Sciences, Tehran, Iran. mhossein110@yahoo.com.
Tehran University of Medical Sciences · IRBabol University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAttention deficit hyperactivity disorder (ADHD) is one of the most common childhood mental health disorders. Stimulant drugs as the most commonly used treatment and first-line therapy for ADHD have side effects. One of the newest approaches to select the best choices and optimize dosages of medications is personalized medicine.

methodsThis historical cohort study was carried out on the data taken from the period of 2008 to 2015. Eligible subjects were included in the study randomly. We used mixed-effects logistic regression models to personalize the dosage of Methylphenidate (MPH) in ADHD. The patients' heterogeneity was considered using subject-specific random effects, which are treated as the realizations of a stochastic process. To recommend a personalized dosage for a new patient, a two-step procedure was proposed. In the first step, we obtained estimates for population parameters. In the second step, the dosage of the drug for a new patient was updated at each follow-up.

resultsOf the 221 children enrolled in the study, 169 (76.5%) were male and 52 (23.5%) were females. The overall mean age at the beginning of the study is 82.5 (± 26.5) months. In multivariable mixed logit model, three variables (severity of ADHD, time duration receiving MPH, and dosage of MPH) had a significant relationship with improvement. Based on this model the personalized dosage of MPH was obtained.

conclusionsTo determine the dosage of MPH for a new patient, the more the severity of baseline is, the more of an initial dose is required. To recommend the dose in the next times, first, the estimation of random coefficient should be updated. The optimum dose increased when the severity of ADHD increased. Also, the results show that the optimum dose of MPH as one proceeds through the period of treatment will decreased.

Indexed as

AlgorithmsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildChild, PreschoolCohort StudiesDose-Response Relationship, DrugFemaleHumansLogistic ModelsMaleMethylphenidateMultivariate AnalysisPrecision MedicineSeverity of Illness IndexTreatment OutcomeCentral Nervous System StimulantsMethylphenidateAttention deficit disorder with hyperactivityLongitudinal dataMethylphenidateMixed-effect modelsPrecision medicineTailor medicine

Identifiers

PMID32156255
PMCPMC7065304
OpenAlexW3011697138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.